Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib Monotherapy or Combination in Myelofibrosis
NCT07734077Phase 2Not yet recruiting
- Sponsor
- John Mascarenhas
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of revumenib in myelofibrosis (MF), sponsored by John Mascarenhas. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
revumenib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07734077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07734077.